The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Abstract
BACKGROUND: Antipsychotic drugs are widely used to manage behavioral and psychological symptoms in dementia despite concerns about their safety. OBJECTIVE: To examine the association between treatment with antipsychotics (both conventional and atypical) and all-cause mortality. DESIGN: Population-based, retrospective cohort study. SETTING: Ontario, Canada. PATIENTS: Older adults with dementia who were followed between 1 April 1997 and 31 March 2003. MEASUREMENTS: The risk for death was determined at 30, 60, 120, and 180 days after the initial dispensing of antipsychotic medication. Two pairwise comparisons were made: atypical versus no antipsychotic use and conventional versus atypical antipsychotic use. Groups were stratified by place of residence (community or long-term care). Propensity score matching was used to adjust for differences in baseline health status. RESULTS: A total of 27,259 matched pairs were identified. New use of atypical antipsychotics was associated with a statistically significant increase in the risk for death at 30 days compared with nonuse in both the community-dwelling cohort (adjusted hazard ratio, 1.31 [95% CI, 1.02 to 1.70]; absolute risk difference, 0.2 percentage point) and the long-term care cohort (adjusted hazard ratio, 1.55 [CI, 1.15 to 2.07]; absolute risk difference, 1.2 percentage points). Excess risk seemed to persist to 180 days, but unequal rates of censoring over time may have affected these results. Relative to atypical antipsychotic use, conventional antipsychotic use was associated with a higher risk for death at all time points. Sensitivity analysis revealed that unmeasured confounders that increase the risk for death could diminish or eliminate the observed associations. LIMITATIONS: Information on causes of death was not available. Many patients did not continue their initial treatments after 1 month of therapy. Unmeasured confounders could affect associations. CONCLUSIONS: Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia. The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A similar black box warning for conventional antipsychotics, based on two observational studies that showed increased risk of mortality in older adults using conventional versus atypical antipsychotics, was announced in 2008.117 118 119”
From Assessment and management of behavioral and psychological symptoms of dementia (2015) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result, it announced a black box warning for the use of atypical antipsychotics for behavioral and psychological symptoms of dementia.”
From Assessment and management of behavioral and psychological symptoms of dementia (2015) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2005, the FDA announced that, based on a re-analysis of 17 placebo controlled trials (several of which were unpublished), atypical antipsychotics were associated with a 1.7-fold increase in mortality compared with placebo.117 118”
From Assessment and management of behavioral and psychological symptoms of dementia (2015) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A meta-analysis found an odds ratio for mortality with these drugs of 1.54 (1.06 to 2.23; Z=2.28; P=0.02), with pooled events of 3.5% mortality for the drug versus 2.3% for placebo.”
From Assessment and management of behavioral and psychological symptoms of dementia (2015) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies have shown that nonpharmacological treatments pose fewer side effects, which render them as safer options [20].”
From Nonpharmacological Interventions to Reduce Behavioral and Psychological Symptoms of Dementia: A Systematic Review (2015) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Rosenbaum, P. R., & Rubin, D. B. (1985) · The American Statistician · doi:10.2307/2683903 · Cited by 6,472
Variable Selection for Propensity Score Models
Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J., & Stürmer, T. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj149 · Cited by 2,336
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Austin, P. C., Grootendorst, P. V., & Anderson, G. M. (2006) · Statistics in Medicine · doi:10.1002/sim.2580 · Cited by 1,138
Self-citationRisk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Effectiveness of Collaborative Care for Older Adults With Alzheimer Disease in Primary Care
Callahan, C. M., Boustani, M. A., Unverzagt, F. W., Austrom, M. G., Damush, T. M., Perkins, A. J., Fultz, B. A., Hui, S. L., Counsell, S. R., & Hendrie, H. C. (2006) · JAMA · doi:10.1001/jama.295.18.2148 · Cited by 799
Research works printed but not linked: 4
- Levy AR, 2003, Can J Clin Pharmacol, 10, 67
- 10.1080/00031305.1985.10479383 · DOI
- Trifirò G, 2006, Pharmacoepidemiol Drug Saf
- Gill SS, 2006, JAMA, 295, 495
Cited by
Sorted by citations
Items 601–618 of 618
Kröger, E., Wilchesky, M., Morin, M., Carmichael, P.-H., Marcotte, M., Misson, L., Plante, J., Voyer, P., & Durand, P. M. (2023) · Figshare · doi:10.6084/m9.figshare.24046140
Watt, J. A., Goodarzi, Z., Veroniki, A. A., Nincic, V., Khan, P. A., Ghassemi, M., Thompson, Y., Lai, Y., Treister, V., Tricco, A. C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12495356
Huang, Y.-T., Steptoe, A., Wei, L., & Zaninotto, P. (2021) · Figshare · doi:10.6084/m9.figshare.17210664
Kumar, S., & Seitz, D. P. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70271
Chen, H., Li, X., Fei, Y., Yu, X., Li, C., Zhao, Y., Wang, J., Yin, Y., Xing, Y., Shan, E., et al. (2026) · Geriatric Nursing · doi:10.1016/j.gerinurse.2026.103887
Li, Z. “., & Belean, C. (2026) · Springer eBooks · doi:10.1007/978-3-032-15772-0_8
Troubles du comportement chez les sujets âgés en Afrique Centrale
Zohoun, I. Y. (2019) · theses.fr (ABES) · doi:10.70675/b23a0608z2004z45fbz8846ze8671311481d
Chu, W., Recchia, D., Islam, S., Sison, C. P., & Sinvani, L. (2026) · Journal of Hospital Medicine · doi:10.1002/jhm.70336
Blonanserin transdermal patch for treating delirium: A case series
Hemmi, M., Yamaguchi, T., Shigetsura, Y., Hira, D., Tanimukai, H., Kawashima, H., Miyoshi, Y., Endo, H., Nakagawa, S., & Terada, T. (2026) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70341
Chapter 11. Treatment of Agitation
Webb, W. M., & Mayorga, A. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551913.lg11
Ram, D., & Moorthy, N. H. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00832-0
Wang, J., & Li, A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1946385
Eassa, N. E., Perez, S. M., Yang, O. J., Boley, A. M., & Lodge, D. J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00432
Giroux, M., Delphin‐Combe, F., Rion, M., Temedda, M. N., Dauphinot, V., Tripoz-dit-Masson, S., Grangé, C., Garnier‐Crussard, A., & Dautricourt, S. (2026) · JMIR Formative Research · doi:10.2196/95542
Backhouse, T. (2014) · UEA Digital Repository (University of East Anglia)
Zaburzenia psychiczne w przebiegu zespołów otępiennych – znaczenie kliniczne i zasady postępowania
Sobów, T. (2012) · DOAJ (DOAJ: Directory of Open Access Journals)
Organische Störungen, Demenzen
Lautenschlager, M. M., Lautenschlager, N. T., & Förstl, H. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_39
Metadata
- Authors
- Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., Gurwitz, J. H., & Rochon, P. A.
- Affiliations
- Harvard University (US)
- From Queen's University, Kingston, Ontario, Canada; Institute for Clinical Evaluative Sciences and University of Toronto, Toronto, Ontario, Canada; Harvard Medical School and Harvard School of Public Health, Boston, Massachusetts; University of British Columbia, Vancouver, British Columbia, Canada; and Meyers Primary Care Institute of the University of Massachusetts Medical School, Fallon Clinic Foundation, and Fallon Community Health Plan, Worcester, Massachusetts.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-06-05
- Volume
- 146
- Issue
- 11
- Pages
- 775-786
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2144855317
- Cited by
- 624
- References
- 66
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 17 · 2023: 22 · 2022: 30 · 2021: 18 · 2020: 27 · 2019: 31 · 2018: 38 · 2017: 36 · 2016: 45 · 2015: 42 · 2014: 30 · 2013: 37 · 2012: 35
- FWCI
- 26.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- antipsychotic drugs, atypical antipsychotics, typical antipsychotics, dementia, all-cause mortality, older adults, behavioral and psychological symptoms of dementia, long-term care, community-dwelling older adults, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Dementia, Female, Humans, Male, Ontario, Sensitivity and Specificity, Time Factors, Antipsychotic Agents, Matched-Pair Analysis, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
